Effect of treatment on the expression of estramustine-binding protein (EMBP) in prostatic cancer patients: an immunohistochemical study.
Estramustine-binding protein (EMBP) was determined immunohistochemically in prostatic cancer (PC) specimens taken from patients before and after therapy. The EMBP staining intensity was correlated with the tumor malignancy grade in untreated PCs. The effect of various treatments (i.e., androgen-withdrawal therapy, treatment with estramustine phosphate or radiation) on the expression of EMBP was also investigated. Although a rabbit polyclonal antiserum raised against rat EMBP was used all through the study, all untreated PCs (n = 53) examined so far displayed a positive immunoreaction. The staining intensity was higher in moderately and poorly differentiated than in well-differentiated tumors. Furthermore, two types of staining patterns were observed, that is, a diffuse type in about 70% and a focal in the remaining cases, which might reflect the multifocal appearance of PCs. The prognostic significance of these staining patterns is discussed. Irrespective of the treatment used, EMBP staining was reduced to lower or undetectable levels in PCs where cytological as well as clinical regression were indicated after 6-30 months of therapy. In nonresponders or patients with refractory disease, however, EMBP expression reappeared and returned to pretreatment levels. In a short-term follow-up, the diminuation of EMBP was evident as early as 10 days after androgen-withdrawal therapy and persisted as long as the patient responded to therapy. When estramustine phosphate was given as secondary treatment to hormone refractory PCs, EMBP decreased to undetectable levels in 3/4 of the specimens, suggesting response to therapy. In conclusion, a decreased EMBP staining was well correlated with favorable cytological regression as well as with clinical regression, whereas unchanged staining intensity was indicative of clinical progression and a poor cytological regression grade. The high levels of EMBP in moderately and poorly differentiated tumors as well as in relapsing PCs, despite continued androgen withdrawal, strongly support a regulation of EMBP that is not under androgenic control. Based on the present findings, we suggest the use of EMBP as a therapy marker. Provided that immunohistochemical measurements can be performed on fine-needle aspirates, EMBP analysis may be a direct and early means to distinguish between responding patients and nonresponders.
Flüchter
S H
SH
Department of Urology, University Hospital, Tübingen, Federal Republic of Germany.
Nelde
H J
HJ
Björk
P
P
Müntzing
J
J
Bichler
K H
KH
D002352:Carrier Proteins / Q000032:analysis / Q000378:metabolism*; D003131:Combined Modality Therapy; D004961:Estramustine / Q000032:analysis / Q000378:metabolism*; D006801:Humans; D007124:Immunoenzyme Techniques; D007150:Immunohistochemistry; D008297:Male; D009367:Neoplasm Staging; D009588:Nitrogen Mustard Compounds / Q000378:metabolism*; D011467:Prostate / Q000032:analysis / Q000378:metabolism / Q000473:pathology; D011471:Prostatic Neoplasms / Q000032:analysis / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D029584:Prostatic Secretory Proteins; D012074:Remission Induction; D013997:Time Factors
D002352:Carrier Proteins; D009588:Nitrogen Mustard Compounds; D029584:Prostatic Secretory Proteins; C028321:estramustine-binding protein; D004961:Estramustine